Cargando…

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

To determine the relationship between the expression of phosphatase and tensin homologue (PTEN) and epidermal growth factor receptor (EGFR) in metastatic colorectal cancer (mCRC) and the clinical outcome of cetuximab-containing chemotherapy. A total of 158 consecutive mCRC patients with wild-type KR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yu, Shi, Yi, Lin, Jing, Ye, Yun-bin, Wang, Xiao-jie, Chen, Gang, Guo, Zeng-qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2015
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616741/ https://www.ncbi.nlm.nih.gov/pubmed/26448020 http://dx.doi.org/10.1097/MD.0000000000001698

Ejemplares similares

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
por: Ucar, Gokhan, et al.
Publicado: (2020)

KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China
por: Lian, Shen-Yi, et al.
Publicado: (2023)

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis
por: Chen, Datian, et al.
Publicado: (2018)

Reliability of digital PCR in detecting KRAS mutation in colorectal cancer using plasma sample: A systematic review and meta-analysis
por: Ye, Peng, et al.
Publicado: (2020)

Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer
por: Hu, Jing, et al.
Publicado: (2016)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

Lung adenocarcinoma with EGFR gene mutation metastatic to the uterine cervix: A case report
por: Wang, Yong, et al.
Publicado: (2020)

Bone metastatic carcinoma with EGFR amplification and mutation: A case report and literature review
por: Du, Hong-Juan, et al.
Publicado: (2023)

MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers
por: Choi, Yong Won, et al.
Publicado: (2016)

Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature
por: Liu, Lei, et al.
Publicado: (2020)

The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients
por: Tang, Xue-Miao, et al.
Publicado: (2017)

The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A protocol for systematic review and meta-analysis
por: Ye, Peng, et al.
Publicado: (2020)

(18)F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer
por: Guan, Jian, et al.
Publicado: (2016)

Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report
por: Xu, Tongpeng, et al.
Publicado: (2017)

Prognostic impact of the Fusobacterium nucleatum status in colorectal cancers
por: Chen, Yanglong, et al.
Publicado: (2019)

Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2018)

Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis
por: Ge, Pu, et al.
Publicado: (2023)

Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients
por: Geng, Rui, et al.
Publicado: (2020)

Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI: A case report
por: Chen, Hui Jun, et al.
Publicado: (2021)

The current status of treatment for colorectal cancer in China: A systematic review
por: Zhang, Yumei, et al.
Publicado: (2017)

Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma
por: Isaka, Tetsuya, et al.
Publicado: (2015)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report
por: Lin, Yu-Lin, et al.
Publicado: (2020)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study
por: Yu, Yuman, et al.
Publicado: (2021)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis
por: Chen, Qiang, et al.
Publicado: (2016)

A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations
por: Song, Si-Yeon, et al.
Publicado: (2020)

KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery
por: Lee, Jeong Won, et al.
Publicado: (2015)

Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer
por: Acikgoz, Ozgur, et al.
Publicado: (2021)

Efficacy and safety of metronomic chemotherapy in maintenance therapy for metastatic colorectal cancer: A systematic review of randomized controlled trials
por: Chen, Li, et al.
Publicado: (2022)

Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report
por: Chen, Sixian, et al.
Publicado: (2021)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

Synchronous Resectable Metastatic Colorectal Cancer: Lymph Node Involvement Predicts Poor Outcome
por: Fu, Jianfei, et al.
Publicado: (2015)

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials
por: Sheng, Jin, et al.
Publicado: (2015)

Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis
por: Hong, Xiaohua, et al.
Publicado: (2022)

Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis
por: Ma, Hongbo, et al.
Publicado: (2019)

EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
por: Yuan, Jin-Qiu, et al.
Publicado: (2017)

Clinical characteristics and establishment of a 2-year-OS predictive model of EGFR mutation-positive patients with pleural invasion of lung adenocarcinoma
por: Kong, Qing, et al.
Publicado: (2023)

Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis
por: Chen, Ke, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ls147hu7vti7k8sq3n303f3ref